Terms: = Prostate cancer AND CDK12, KIAA0904, CRKRS, 51755, ENSG00000167258, CRK7, CRKR, Q9NYV4 AND Treatment
48 results:
1. cdk12 regulates angiogenesis of advanced prostate cancer by IGFBP3.
Zhong K; Luo W; Li N; Tan X; Li Y; Yin S; Huang Y; Fang L; Ma W; Cai Y; Yin Y
Int J Oncol; 2024 Feb; 64(2):. PubMed ID: 38186306
[TBL] [Abstract] [Full Text] [Related]
2. DNA Damage Response and Mismatch Repair Gene Defects in Advanced and Metastatic prostate cancer.
Akhoundova D; Francica P; Rottenberg S; Rubin MA
Adv Anat Pathol; 2024 Mar; 31(2):61-69. PubMed ID: 38008971
[TBL] [Abstract] [Full Text] [Related]
3. Inhibition of the Cyclin K-cdk12 complex induces DNA damage and increases the effect of androgen deprivation therapy in prostate cancer.
Frei K; Schecher S; Daher T; Hörner N; Richter J; Hildebrand U; Schindeldecker M; Witzel HR; Tsaur I; Porubsky S; Gaida MM; Roth W; Tagscherer KE
Int J Cancer; 2024 Mar; 154(6):1082-1096. PubMed ID: 37916780
[TBL] [Abstract] [Full Text] [Related]
4. Comprehensive genomic profiling testing in Japanese castration-resistant prostate cancer patients: results of a single-center retrospective cohort study.
Fukushima T; Goto K; Hayashi T; Ikeda K; Hatayama T; Yamanaka R; Iwane K; Tasaka R; Kohada Y; Takemoto K; Kobatake K; Goriki A; Toshida A; Nakahara H; Motonaga M; Tokumo K; Fujii Y; Hayes CN; Okamoto W; Kubo T; Matsumoto T; Shiota M; Yamamoto N; Urabe Y; Hiyama E; Arihiro K; Hinoi T; Hinata N
Jpn J Clin Oncol; 2024 Feb; 54(2):175-181. PubMed ID: 37899139
[TBL] [Abstract] [Full Text] [Related]
5. Prediction of Resistance to
Sartor O; Ledet E; Huang M; Schwartz J; Lieberman A; Lewis B; Layton J; Barata P; Jang A; Hawkins M; Pocha O; Lanka S; Harris K
J Nucl Med; 2023 Nov; 64(11):1721-1725. PubMed ID: 37770113
[No Abstract] [Full Text] [Related]
6. Rucaparib for the treatment of Metastatic Castration-resistant prostate cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study.
Abida W; Campbell D; Patnaik A; Bryce AH; Shapiro J; Bambury RM; Zhang J; Burke JM; Castellano D; Font A; Ganju V; Hardy-Bessard AC; McDermott R; Sautois B; Spaeth D; Voog E; Piulats JM; Pintus E; Ryan CJ; Merseburger AS; Daugaard G; Heidenreich A; Fizazi K; Loehr A; Despain D; Simmons AD; Dowson M; Go J; Watkins SP; Chowdhury S
Eur Urol; 2023 Sep; 84(3):321-330. PubMed ID: 37277275
[TBL] [Abstract] [Full Text] [Related]
7. Early Plasma Circulating Tumor DNA as a Potential Biomarker of Disease Recurrence in Non-metastatic prostate cancer.
Fei X; Du X; Gong Y; Liu J; Fan L; Wang J; Wang Y; Zhu Y; Pan J; Dong B; Xue W
Cancer Res Treat; 2023 Jul; 55(3):969-977. PubMed ID: 36915250
[TBL] [Abstract] [Full Text] [Related]
8. Pan-cancer association of DNA repair deficiencies with whole-genome mutational patterns.
Sørensen SG; Shrikhande A; Poulsgaard GA; Christensen MH; Bertl J; Laursen BE; Hoffmann ER; Pedersen JS
Elife; 2023 Mar; 12():. PubMed ID: 36883553
[TBL] [Abstract] [Full Text] [Related]
9. Homologous recombination repair gene mutations in Malaysian prostate cancer patients.
Saeidi H; Raju CS; Ismail P; Raub SHA; Omar N; Hisyam Bakrin I
Cell Mol Biol (Noisy-le-grand); 2022 Aug; 68(8):22-26. PubMed ID: 36800845
[TBL] [Abstract] [Full Text] [Related]
10. A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant prostate cancer (mCRPC) with Bone Metastases (COMRADE).
Pan E; Xie W; Ajmera A; Araneta A; Jamieson C; Folefac E; Hussain A; Kyriakopoulos CE; Olson A; Parikh M; Parikh R; Saraiya B; Ivy SP; Van Allen EM; Lindeman NI; Kochupurakkal BS; Shapiro GI; McKay RR
Mol Cancer Ther; 2023 Apr; 22(4):511-518. PubMed ID: 36780008
[TBL] [Abstract] [Full Text] [Related]
11. The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: The multi-institutional observational ZENSHIN study.
Uemura H; Oya M; Kamoto T; Sugimoto M; Shinozaki K; Morita K; Koto R; Takahashi M; Nii M; Shin E; Nonomura N
Cancer Med; 2023 Mar; 12(5):5265-5274. PubMed ID: 36358026
[TBL] [Abstract] [Full Text] [Related]
12. MAPK8IP2 is a potential prognostic biomarker and promote tumor progression in prostate cancer.
Zeng Z; He W; Jiang Y; Jiang H; Cheng X; Deng W; Zhou X; Zhang C; Wang G
BMC Cancer; 2022 Nov; 22(1):1162. PubMed ID: 36357836
[TBL] [Abstract] [Full Text] [Related]
13. Molecular Genetics of prostate cancer and Role of Genomic Testing.
Akhoundova D; Feng FY; Pritchard CC; Rubin MA
Surg Pathol Clin; 2022 Dec; 15(4):617-628. PubMed ID: 36344179
[TBL] [Abstract] [Full Text] [Related]
14. CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer.
Sun R; Wei T; Ding D; Zhang J; Chen S; He HH; Wang L; Huang H
Proc Natl Acad Sci U S A; 2022 Sep; 119(39):e2205509119. PubMed ID: 36129942
[TBL] [Abstract] [Full Text] [Related]
15. Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic prostate cancer Following Progression on Androgen-Targeting Therapies.
Zurita AJ; Graf RP; Villacampa G; Raskina K; Sokol E; Jin D; Antonarakis ES; Li G; Huang RSP; Casanova-Salas I; Vivancos A; Carles J; Ross JS; Schrock AB; Oxnard GR; Mateo J
JCO Precis Oncol; 2022 Jul; 6():e2200195. PubMed ID: 35820087
[TBL] [Abstract] [Full Text] [Related]
16. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.
He Y; Xu W; Xiao YT; Huang H; Gu D; Ren S
Signal Transduct Target Ther; 2022 Jun; 7(1):198. PubMed ID: 35750683
[TBL] [Abstract] [Full Text] [Related]
17. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH
Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618
[TBL] [Abstract] [Full Text] [Related]
18. Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
Leibowitz BD; Dougherty BV; Bell JSK; Kapilivsky J; Michuda J; Sedgewick AJ; Munson WA; Chandra TA; Dry JR; Beaubier N; Igartua C; Taxter T
BMC Cancer; 2022 May; 22(1):587. PubMed ID: 35643464
[TBL] [Abstract] [Full Text] [Related]
19. Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive prostate cancer.
Freeman MN; Jang A; Zhu J; Sanati F; Nandagopal L; Ravindranathan D; Desai A; Phone A; Nussenzveig R; Jaeger E; Caputo SA; Koshkin VS; Swami U; Basu A; Bilen MA; Agarwal N; Sartor O; Burgess EF; Barata PC
Oncologist; 2022 Mar; 27(3):220-227. PubMed ID: 35274720
[TBL] [Abstract] [Full Text] [Related]
20. Castration-resistant prostate cancer patient presenting with whole genome doubling with CDK-12 mutation.
Baba Y; Kosaka T; Kobayashi H; Nakamura K; Mikami S; Nishihara H; Nakanishi M; Oya M
BMC Med Genomics; 2022 Feb; 15(1):32. PubMed ID: 35183184
[TBL] [Abstract] [Full Text] [Related]
[Next]
